Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 5,964 Shares

Liquidia Co. (NASDAQ:LQDA - Get Free Report) General Counsel Russell Schundler sold 5,964 shares of the stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $80,931.48. Following the transaction, the general counsel now directly owns 570,301 shares in the company, valued at approximately $7,738,984.57. This represents a 1.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Liquidia Stock Performance

NASDAQ LQDA traded down $0.43 during trading hours on Monday, hitting $13.29. 678,752 shares of the company traded hands, compared to its average volume of 968,593. Liquidia Co. has a twelve month low of $8.26 and a twelve month high of $16.81. The business's 50-day moving average is $14.65 and its 200-day moving average is $12.82. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -8.15 and a beta of 0.23.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The company had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. Analysts predict that Liquidia Co. will post -1.51 EPS for the current year.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Liquidia during the first quarter worth $911,000. GAMMA Investing LLC grew its holdings in Liquidia by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after acquiring an additional 1,173 shares during the period. Rhumbline Advisers lifted its stake in Liquidia by 6.0% in the first quarter. Rhumbline Advisers now owns 85,463 shares of the company's stock valued at $1,261,000 after buying an additional 4,811 shares during the period. Whitcomb & Hess Inc. grew its position in shares of Liquidia by 85.3% during the 1st quarter. Whitcomb & Hess Inc. now owns 21,300 shares of the company's stock worth $314,000 after buying an additional 9,805 shares during the period. Finally, California State Teachers Retirement System grew its holdings in Liquidia by 17.5% in the fourth quarter. California State Teachers Retirement System now owns 51,928 shares of the company's stock worth $611,000 after purchasing an additional 7,725 shares during the period. 64.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LQDA has been the subject of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $25.00 target price on shares of Liquidia in a research note on Thursday, April 10th. HC Wainwright restated a "buy" rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. Finally, Scotiabank reiterated an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $26.63.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).